Table 3.
Multivariate analysis of factors that influence transplant outcomes.
| Outcomes and significant factors | All patients | Myeloid cohort | Lymphoid cohort | |||
|---|---|---|---|---|---|---|
| P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | |
| 1. EBV viremia* | ||||||
| ATG-G vs ATG-F | <0.0001 | 2.58 (1.61–4.13) | 0.007 | 2.51 (1.28–4.93) | 0.004 | 2.66 (1.37–5.14) |
| Male vs Female | 0.042 | 1.57 (1.02–2.41) | ||||
| Myeloid vs Lymphoid | 0.0005 | 0.48 (0.31–0.72) | ||||
| 2. CMV viremia* | ||||||
| ATG-G vs ATG-F | 0.008 | 1.70 (1.15–2.51) | 0.005 | 1.76 (1.19–2.59) | ||
| 3. 3-yr CIR | ||||||
| CR1 vs >CR1 | 0.029 | 0.53 (0.30–0.94) | ||||
| iKIR-HLA C variation (D vs U+I) | 0.033 | 1.95 (1.06–3.61) | 0.019 | 2.95 (1.19–7.27) | ||
| 4. 3-yr OS | ||||||
| Myeloid vs Lymphoid | 0.006 | 0.49 (0.29–0.82) | ||||
| CR1 vs >CR1 | 0.004 | 0.46 (0.27–0.78) | 0.029 | 0.45 (0.22–0.92) | ||
| iKIR-HLA C variation (D vs U+I) | 0.001 | 3.74 (1.66–8.39) | ||||
| 5. 3-yr DFS | ||||||
| Myeloid vs lymphoid | 0.003 | 0.47 (0.28–0.77) | ||||
| CR1 vs >CR1 | 0.009 | 0.51 (0.31–0.84) | 0.034 | 0.47 (0.24–0.94) | ||
| iKIR-HLA C variation (D vs U+I) | 0.0004 | 4.05 (1.87–8.80) | ||||
*Estimations of cumulative incidence are given at 100 days post-HSCT for aGVHD; 180 days post-HSCT for EBV and CMV viremia.
Significant factors with P < 0.05 were in bold type.